377 related articles for article (PubMed ID: 18008359)
1. Multiple biomarkers improve prediction of bladder cancer recurrence and mortality in patients undergoing cystectomy.
Shariat SF; Karakiewicz PI; Ashfaq R; Lerner SP; Palapattu GS; Cote RJ; Sagalowsky AI; Lotan Y
Cancer; 2008 Jan; 112(2):315-25. PubMed ID: 18008359
[TBL] [Abstract][Full Text] [Related]
2. p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer.
Shariat SF; Tokunaga H; Zhou J; Kim J; Ayala GE; Benedict WF; Lerner SP
J Clin Oncol; 2004 Mar; 22(6):1014-24. PubMed ID: 14981102
[TBL] [Abstract][Full Text] [Related]
3. Prospective evaluation of a molecular marker panel for prediction of recurrence and cancer-specific survival after radical cystectomy.
Lotan Y; Bagrodia A; Passoni N; Rachakonda V; Kapur P; Arriaga Y; Bolenz C; Margulis V; Raj GV; Sagalowsky AI; Shariat SF
Eur Urol; 2013 Sep; 64(3):465-71. PubMed ID: 23571005
[TBL] [Abstract][Full Text] [Related]
4. Predictive value of combined immunohistochemical markers in patients with pT1 urothelial carcinoma at radical cystectomy.
Shariat SF; Bolenz C; Godoy G; Fradet Y; Ashfaq R; Karakiewicz PI; Isbarn H; Jeldres C; Rigaud J; Sagalowsky AI; Lotan Y
J Urol; 2009 Jul; 182(1):78-84; discussion 84. PubMed ID: 19447418
[TBL] [Abstract][Full Text] [Related]
5. Nomogram for predicting disease recurrence after radical cystectomy for transitional cell carcinoma of the bladder.
Karakiewicz PI; Shariat SF; Palapattu GS; Gilad AE; Lotan Y; Rogers CG; Vazina A; Gupta A; Bastian PJ; Perrotte P; Sagalowsky AI; Schoenberg M; Lerner SP
J Urol; 2006 Oct; 176(4 Pt 1):1354-61; discussion 1361-2. PubMed ID: 16952631
[TBL] [Abstract][Full Text] [Related]
6. Use of combined apoptosis biomarkers for prediction of bladder cancer recurrence and mortality after radical cystectomy.
Karam JA; Lotan Y; Karakiewicz PI; Ashfaq R; Sagalowsky AI; Roehrborn CG; Shariat SF
Lancet Oncol; 2007 Feb; 8(2):128-36. PubMed ID: 17267327
[TBL] [Abstract][Full Text] [Related]
7. Predictive value of cell cycle biomarkers in nonmuscle invasive bladder transitional cell carcinoma.
Shariat SF; Ashfaq R; Sagalowsky AI; Lotan Y
J Urol; 2007 Feb; 177(2):481-7; discussion 487. PubMed ID: 17222615
[TBL] [Abstract][Full Text] [Related]
8. Nomograms provide improved accuracy for predicting survival after radical cystectomy.
Shariat SF; Karakiewicz PI; Palapattu GS; Amiel GE; Lotan Y; Rogers CG; Vazina A; Bastian PJ; Gupta A; Sagalowsky AI; Schoenberg M; Lerner SP
Clin Cancer Res; 2006 Nov; 12(22):6663-76. PubMed ID: 17121885
[TBL] [Abstract][Full Text] [Related]
9. Expression of cell cycle-related molecular markers in patients treated with radical cystectomy for squamous cell carcinoma of the bladder.
Youssef RF; Shariat SF; Kapur P; Kabbani W; Ghoneim T; King E; Cockburn A; Mosbah A; Abol-Enein H; Ghoneim M; Lotan Y
Hum Pathol; 2011 Mar; 42(3):347-55. PubMed ID: 21111452
[TBL] [Abstract][Full Text] [Related]
10. Correlation of cyclin D1 and E1 expression with bladder cancer presence, invasion, progression, and metastasis.
Shariat SF; Ashfaq R; Sagalowsky AI; Lotan Y
Hum Pathol; 2006 Dec; 37(12):1568-76. PubMed ID: 16949911
[TBL] [Abstract][Full Text] [Related]
11. p53 predictive value for pT1-2 N0 disease at radical cystectomy.
Shariat SF; Lotan Y; Karakiewicz PI; Ashfaq R; Isbarn H; Fradet Y; Bastian PJ; Nielsen ME; Capitanio U; Jeldres C; Montorsi F; Müller SC; Karam JA; Heukamp LC; Netto G; Lerner SP; Sagalowsky AI; Cote RJ
J Urol; 2009 Sep; 182(3):907-13. PubMed ID: 19616250
[TBL] [Abstract][Full Text] [Related]
12. Association of angiogenesis related markers with bladder cancer outcomes and other molecular markers.
Shariat SF; Youssef RF; Gupta A; Chade DC; Karakiewicz PI; Isbarn H; Jeldres C; Sagalowsky AI; Ashfaq R; Lotan Y
J Urol; 2010 May; 183(5):1744-50. PubMed ID: 20299037
[TBL] [Abstract][Full Text] [Related]
13. Association of cyclin D1 and E1 expression with disease progression and biomarkers in patients with nonmuscle-invasive urothelial cell carcinoma of the bladder.
Shariat SF; Ashfaq R; Sagalowsky AI; Lotan Y
Urol Oncol; 2007; 25(6):468-75. PubMed ID: 18047954
[TBL] [Abstract][Full Text] [Related]
14. Neurofuzzy modeling to determine recurrence risk following radical cystectomy for nonmetastatic urothelial carcinoma of the bladder.
Catto JW; Abbod MF; Linkens DA; Larré S; Rosario DJ; Hamdy FC
Clin Cancer Res; 2009 May; 15(9):3150-5. PubMed ID: 19336522
[TBL] [Abstract][Full Text] [Related]
15. p53 and p21 Expression levels predict organ preservation and survival in invasive bladder carcinoma treated with a combined-modality approach.
Garcia del Muro X; Condom E; Vigués F; Castellsagué X; Figueras A; Muñoz J; Solá J; Soler T; Capellà G; Germà JR
Cancer; 2004 May; 100(9):1859-67. PubMed ID: 15112266
[TBL] [Abstract][Full Text] [Related]
16. Predictive value of p53 and pRb immunostaining in locally advanced bladder cancer treated with cystectomy.
Jahnson S; Karlsson MG
J Urol; 1998 Oct; 160(4):1291-6. PubMed ID: 9751338
[TBL] [Abstract][Full Text] [Related]
17. Multi-institutional validation of the predictive value of Ki-67 labeling index in patients with urinary bladder cancer.
Margulis V; Lotan Y; Karakiewicz PI; Fradet Y; Ashfaq R; Capitanio U; Montorsi F; Bastian PJ; Nielsen ME; Müller SC; Rigaud J; Heukamp LC; Netto G; Lerner SP; Sagalowsky AI; Shariat SF
J Natl Cancer Inst; 2009 Jan; 101(2):114-9. PubMed ID: 19141773
[TBL] [Abstract][Full Text] [Related]
18. Risk stratification of organ confined bladder cancer after radical cystectomy using cell cycle related biomarkers.
Shariat SF; Chromecki TF; Cha EK; Karakiewicz PI; Sun M; Fradet Y; Isbarn H; Scherr DS; Bastian PJ; Pummer K; Fajkovic H; Sagalowsky AI; Ashfaq R; Doblinger M; Cote RJ; Lotan Y
J Urol; 2012 Feb; 187(2):457-62. PubMed ID: 22177145
[TBL] [Abstract][Full Text] [Related]
19. Positive surgical margins in soft tissue following radical cystectomy for bladder cancer and cancer specific survival.
Dotan ZA; Kavanagh K; Yossepowitch O; Kaag M; Olgac S; Donat M; Herr HW
J Urol; 2007 Dec; 178(6):2308-12; discussion 2313. PubMed ID: 17936804
[TBL] [Abstract][Full Text] [Related]
20. Combination of multiple molecular markers can improve prognostication in patients with locally advanced and lymph node positive bladder cancer.
Shariat SF; Chade DC; Karakiewicz PI; Ashfaq R; Isbarn H; Fradet Y; Bastian PJ; Nielsen ME; Capitanio U; Jeldres C; Montorsi F; Lerner SP; Sagalowsky AI; Cote RJ; Lotan Y
J Urol; 2010 Jan; 183(1):68-75. PubMed ID: 19913255
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
